Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2004-05-28
2008-09-16
Anderson, Rebecca L (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S254090, C514S414000, C514S339000, C514S378000, C514S411000, C548S466000
Reexamination Certificate
active
07425553
ABSTRACT:
The present invention relates to novel Triheterocyclic Compounds, compositions comprising a Triheterocyclic Compound, and methods useful for treating or preventing cancer or a neoplastic disorder comprising administering a Triheterocyclic Compound. The compounds, compositions, and methods of the invention are also useful for inhibiting the growth of a cancer cell or neoplastic cell, treating or preventing a viral infection, or inhibiting the replication and/or infectivity of a virus.
REFERENCES:
patent: 5248782 (1993-09-01), Haugland et al.
patent: 5338854 (1994-08-01), Kang et al.
patent: 5573909 (1996-11-01), Singer et al.
patent: 5691334 (1997-11-01), Doria et al.
patent: 6071947 (2000-06-01), D'Alessio et al.
patent: 6956022 (2005-10-01), Tamura et al.
patent: 2003/0215444 (2003-11-01), Elliott
patent: 2005/0014802 (2005-01-01), Attardo et al.
patent: 2005/0106148 (2005-05-01), Kay et al.
patent: 2005/0267073 (2005-12-01), Dairi et al.
patent: 2006/0035945 (2006-02-01), Attardo et al.
patent: 903 733 (1999-03-01), None
patent: 756 200 (1999-11-01), None
patent: 1644363 (2006-04-01), None
patent: 1853255 (2007-11-01), None
patent: 61034403 (1986-02-01), None
patent: 5-86374 (1993-12-01), None
patent: 08003136 (1996-01-01), None
patent: 10120562 (1998-05-01), None
patent: 10120563 (1998-05-01), None
patent: 2000275435 (2000-10-01), None
patent: 2001223081 (2001-08-01), None
patent: 2001223082 (2001-08-01), None
patent: 2001257077 (2001-09-01), None
patent: 2001297881 (2001-10-01), None
patent: 2001307884 (2001-11-01), None
patent: 2001330729 (2001-11-01), None
patent: 2001330730 (2001-11-01), None
patent: WO 93/09185 (1993-05-01), None
patent: WO 93/23492 (1993-11-01), None
patent: WO 98/40380 (1998-09-01), None
patent: WO 99/30709 (1999-06-01), None
patent: WO 00/24893 (2000-05-01), None
patent: WO 00/033836 (2000-06-01), None
patent: WO 01/55131 (2001-08-01), None
patent: WO 02/051409 (2002-07-01), None
patent: WO 03/008410 (2003-01-01), None
patent: WO 2004/014881 (2004-02-01), None
patent: WO 2004/106328 (2004-12-01), None
patent: WO 2005/117908 (2005-12-01), None
patent: WO 2006/089397 (2006-08-01), None
Berge et al. Journal of Pharmaceutical Sciences, vol. 66, No. 1, Jan. 1977, pp. 1-19.
Beilstein Records No. 8747436, “2-(5-methoxy-1H-indol-2-yl)-4-methoxy-5-<(5-undecyl-2H-pyrrol-2-ylidene) methyl>-2,2′-bi-1H-pyrrole hydrochloride” 2001.
Beilstein Records No. 8747419, “2-(5-chloro-1H-indol-2-yl)-4-methoxy-5-<(5-undecyl-2H-pyrrol-2-ylidene) methyl>-2,2′-bi-1H-pyrrole hydrochloride” 2001.
Beilstein Records No. 8746619 “2-(1H-indol-2-yl)-4-methoxy-5-<(5-undecyl-2H-pyrrol-2-ylidene) methyl>-2,2′-bi-1H-pyrrole hydrochloride” 2001.
Beilstein Records No. 8739149, “2-(5-methoxy-1H-indol-2-yl)-4-methoxy-5-<(5-undecyl-2H-pyrrol-2-ylidene) methyl>-2,2′-bi-1H-pyrrole” 2001.
Beilstein Records No. 8738700, “2-(5-chloro-1H-indol-2-yl)-4-methoxy-5-<(5-undecyl-2H-pyrrol-2-ylidene) methyl>-2,2′-bi-1H-pyrrole” 2001.
Beilstein Records No. 8737177, “2-(1H-indol-2-yl)-4-methoxy-5-<(5-undecyl-2H-pyrrol-2-ylidene) methyl>-2,2′-bi-1H-pyrrole” 2001.
Bizhev et al., 1983, “Condensations of a pyrrole aldehyde with 1,2-diamines, to products with pharmacological and analytical interest,” XP002297006 from STN Database Accession No. 1983:438416 abstract and the compound with the RN '86406-77-1!: “1H-pyrrole-2, 4-dcarboxylic acid, 5-(1H-benzimidazol-2-yl)-3-methyl-, diethyl ester” Farmatsiya (Sofia, Bulgaria) 33(1):1-6.
Boger, 1988, “Total synthesis of Prodigiosin, prodigiosene, and desmethoxyprodigiosin: Diels-Alder reactions of heterocyclic azadienes and development of an effective palladium(II)-promoted 2,2′-bipyrrole coupling procedure,” J. Org. Chem. 53:1405-1415.
Chem, Qing-qi et al., 1995, “Syntheses of 1,2-bis ′5-(2′-benzoxazolyl)-pyrrole-2-yl] ethenes,” XP002297005 from STN Database Accession No. 1995:766242 abstract and the compound with the RN 168002-55-9!: “1H-pyrrole-2-carboxylic acid, 5-(2-benzoxazolyl)-3-methyl, ethyl ester” Dyes and Pigments 28(4):291-295.
D'Alessio et al., 2000, “Synthesis and immunosuppressive activity of novel prodigiosin derivatives,” J. Med. Chem. 43(13):2557-2565.
Derwent Chemical Registry Resource Accession No. DCR-214226, 2003.
Developmental Therapeutics Program of the NCI/NIH website, 2000.
Martinez et al., 1981, “Preparation and lithiation of N-(N,N-dimethylamino)pyrrole: a useful reagent for the preparation of 2-acylpyrroles,” J. Org. Chem., 46:3760-3761.
Minato et al., 1981, “Palladium-phosphine complex catalyzed cross-coupling reaction of 1-methyl-2-pyrrolyl-magnesium bromide and -zinc chloride with organic halides,” Tetrahedron Lett. 22:5319-5322.
Nicolaou et al., 1996, “Phosphate Prodrugs for Amines Utilizing a Fast Intramolecular Hydroxy Amide Lactonization,” J. Org. Chem. 61:8636-8641.
Zhu et al., 2000, “Phosphate prodrugs of PD154075,” Bioorganic & Medicinal Chemistry Letters, Oxford, GB 10(10):1121-1124.
Arnett et al., “The American Rheumatism Association 1987 Revised Criteria for the Classification of Rheumatoid Arthritis”, Arthritis Rheum 31(3):315-324, 1988.
Baldino et al., “Indoloprodigiosins from the C-10 Bipyrrolic Precursor: New Antiproliferative Prodigiosin Analogs”, Bioorg Med Chem Lett 16:701-704, 2006.
Burmester et al., “Mononuclear Phagocytes and Rheumatoid Synovitis”, Arthritis Rheum 40(1):5-18, 1997.
D'Alessio and Rossi, “Short Synthesis of Undecylprodigiosine. A New Route to 2,2′-Bipyrrolyl-Pyrromethene Systems”, Synlett 513-514, 1996.
Firestein and Zvaifler, “How Important Are T Cells in Chronic Rheumatoid Synovitis?”, Arthritis Rheum 33(6):768-773, 1990.
Fürstner, “Chemistry and Biology of Roseophilin and the Prodigiosin Alkaloids: A Survey of the Last 2500 Years”, Angew Chem Int Ed 42:3582-3603, 2003.
Goronzy and Weyand, “T Cells in Rheumatoid Arthritis. Paradigms and Facts”, Rheum Dis Clin North Am 21(3):655-74, 1995.
Manderville, “Synthesis, Proton-Affinity and Anti-Cancer Properties of the Prodigiosin-Group Natural Products”, Curr Med Chem—Anti-Cancer Agents 1:195-218, 2001.
Panayi et al., “The Importance of the T Cell in Initiating and Maintaining the Chronic Synovitis of Rheumatoid Arthritis”, Arthritis Rheum 35(7):729-735, 1992.
Rapoport and Holden, “The Synthesis of Prodigiosin”, J Am Chem Soc 84:635-642, 1962.
Todd et al., “A Molecular Basis for MHC Class II—Associated Autoimmunity”, Science 240:1003-1009, 1988.
Viallet, U.S. Appl. No. 11/895,012, entitled “Methods for Treating Arthritis using Triheterocyclic Compounds”, filed Aug. 22, 2007.
Viallet and O'Brien, U.S. Appl. No. 11/825,194, entitled “Methods for Treating or Preventing Anemia or Thrombocytopenia using a Triheierocyclic Compound”, filed Jul. 5, 2007.
Attardo Giorgio
Doyle Terrence W.
Lavallee Jean-Francois
Rioux Elise
Anderson Rebecca L
Gemin X Pharmaceuticals Canada inc.
Wilson Sonsini Goodrich & Rosati
LandOfFree
Triheterocyclic compounds, compositions, and methods for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Triheterocyclic compounds, compositions, and methods for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Triheterocyclic compounds, compositions, and methods for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3988733